Document Detail

Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia.
MedLine Citation:
PMID:  3044508     Owner:  NLM     Status:  MEDLINE    
Cholestyramine and bezafibrate were compared individually and in combination in the treatment of 18 patients with heterozygous familial hypercholesterolaemia. The study used a double blind, placebo controlled block design with a placebo run in period of two months followed by three phases of active treatment, each of two months' duration. Patients were randomly allocated to one of the six possible sequences of medication so that three patients would be treated with each sequence. Two patients withdrew from the study before completion. The median concentration of total cholesterol decreased from 9.65 mmol/l (interquartile range 8.62 to 8.72) to 7.24 mmol/l (6.70 to 7.52) with cholestyramine, to 8.09 mmol/l (7.18 to 8.68) with bezafibrate, and to 6.31 mmol/l (5.84 to 7.27) with the combination. This fall was due almost entirely to a decrease in the low density lipoprotein cholesterol concentration, and the combination was significantly more effective than either drug alone. The 98% confidence intervals for the median differences between the combination and cholestyramine and the combination and bezafibrate were 0.04 to 1.49 mmol/l and 0.51 to 2.18 mmol/l respectively. These results suggest that this combination is an effective and useful treatment in heterozygous familial hypercholesterolaemia.
L D Curtis; A C Dickson; K L Ling; J Betteridge
Related Documents :
22693418 - Repeatability and interobserver reproducibility of artemis-2 high-frequency ultrasound ...
10846948 - Development of thyroid follicular adenoma on simvastatin therapy.
8801868 - Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. a t...
19917888 - Effects of statin therapy according to plasma high-sensitivity c-reactive protein conce...
11412288 - Optimizing peroperative compliance with peep during upper abdominal surgery: effects on...
22345418 - Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  BMJ (Clinical research ed.)     Volume:  297     ISSN:  0959-8138     ISO Abbreviation:  BMJ     Publication Date:  1988 Jul 
Date Detail:
Created Date:  1988-10-05     Completed Date:  1988-10-05     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8900488     Medline TA:  BMJ     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  173-5     Citation Subset:  AIM; IM    
Department of Medicine, University College, London.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bezafibrate / therapeutic use*
Cholestyramine Resin / therapeutic use*
Clinical Trials as Topic
Double-Blind Method
Drug Therapy, Combination
Hyperlipoproteinemia Type II / drug therapy*
Middle Aged
Random Allocation
Reg. No./Substance:
11041-12-6/Cholestyramine Resin; 41859-67-0/Bezafibrate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
Next Document:  Pneumocystis carinii pneumonia: detection of parasites in sputum and bronchoalveolar lavage fluid by...